Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GRCL
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Gracell Biotechnologies Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 989.87M
- Ent value
- -418.66M
- Price/Sales
- -
- Price/Book
- 0.61
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 390.43%
- 3 year return
- -26.83%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
GRCL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.61 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 96.57M |
| EPS (TTM) | -5.67 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -561.55M |
| Net income (TTM) | -475.95M |
| EPS (TTM) | -5.67 |
| EPS (1y forward) | -0.18 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.68B |
| Net receivables | 0.00 |
| Total current assets | 1.77B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 108.67M |
| Total assets | 1.89B |
| Accounts payable | 0.00 |
| Short/Current long term debt | 115.82M |
| Total current liabilities | 229.48M |
| Total liabilities | 268.86M |
| Shareholder's equity | 1.62B |
| Net tangible assets | 1.62B |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -29.36% |
| Return on Assets | -25.18% |
| Return on Invested Capital | -27.43% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| GRCL | S&P500 | |
| Current price drop from All-time high | -66.47% | - |
| Highest price drop | -95.26% | -56.47% |
| Date of highest drop | 25 Apr 2023 | 9 Mar 2009 |
| Avg drop from high | -76.53% | -11.07% |
| Avg time to new high | 157 days | 12 days |
| Max time to new high | 766 days | 1805 days |
COMPANY DETAILS
Marketcap
989.87M
Marketcap category
Small-cap
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.
Employees
314
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner